ADYX (Adynxx) EBIT: $-6.28 Mil (TTM As of Sep. 2019)


ADYX Adynxx Inc ADYX
16 GF Score
Price $0.00
View Full Analysis

What is Adynxx EBIT?

Adynxx ADYX -99.00% 16 EBIT is $-6.28 Mil as of Sep. 2019. GuruFocus rates ADYX with a GF Score™ of 16/100.

Adynxx's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2019 was $-1.67 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2019 was $-6.28 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Adynxx's annualized ROC % for the quarter that ended in Sep. 2019 was -71.49%. Adynxx's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was -905.62%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.


Adynxx  (OTCPK:ADYX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Adynxx's annualized ROC % for the quarter that ended in Sep. 2019 is calculated as:

ROC % (Q: Sep. 2019 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2019 ) + Invested Capital (Q: Sep. 2019 ))/ count )
=-6.688 * ( 1 - 0% )/( (9.036 + 9.675)/ 2 )
=-6.688/9.3555
=-71.49 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2019) data.

2. Joel Greenblatt's definition of Return on Capital:

Adynxx's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2019 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2019  Q: Sep. 2019
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-6.688/( ( (0.785 + max(-1.352, 0)) + (0.692 + max(-2.619, 0)) )/ 2 )
=-6.688/( ( 0.785 + 0.692 )/ 2 )
=-6.688/0.7385
=-905.62 %

where Working Capital is:

Working Capital(Q: Jun. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.876) - (3.228 + 0 + 0)
=-1.352

Working Capital(Q: Sep. 2019 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.213) - (4.832 + 0 + 0)
=-2.619

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Adynxx's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2019 )
=-6.276/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adynxx EBIT Related Terms


Adynxx EBIT Historical Data

* Premium members only.

The historical data trend for Adynxx's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adynxx EBIT Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.43 -27.37 -31.21 -4.76 -5.30

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.97 -1.38 -0.98 -2.25 -1.67

ADYX vs TRPX, MITI, RASP: EBIT Comparison

For the Biotechnology subindustry, Adynxx's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adynxx EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Adynxx's EV-to-EBIT falls into.


ADYX
16GF Score
Adynxx Inc ADYX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Adynxx EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.28 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-6.28 Mil mean?
Adynxx (ADYX) has a EBIT of $-6.28 Mil as of Sep. 2019. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Adynxx.
Is Adynxx's EBIT too high?
Adynxx's current EBIT is $-6.28 Mil. Overall, Adynxx has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Adynxx's EBIT compare to TRPX and MITI?
Adynxx's EBIT of $-6.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Adynxx. Adynxx's current EBIT is $-6.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adynxx stock overvalued right now?
Adynxx (ADYX) has a current EBIT of $-6.28 Mil. The current EBIT is $-6.28 Mil. Adynxx's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Adynxx (ADYX), the current EBIT is $-6.28 Mil as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Adynxx Business Description

Address 100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
16GF Score

Get the complete analysis for ADYX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price